<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>A1646</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Albertus Extra Bold";
	panose-1:2 14 8 2 4 3 4 2 2 4;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 6 4 5 2 3 4;}
@font-face
	{font-family:Albertus;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	background:navy;
	font-size:12.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:9.0pt;
	font-family:"Segoe UI",sans-serif;
	letter-spacing:.2pt;}
p.FronterPage, li.FronterPage, div.FronterPage
	{mso-style-name:FronterPage;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.Para10pt
	{mso-style-name:Para10pt;
	font-family:"Times New Roman",serif;}
p.PrefileFronterTitle, li.PrefileFronterTitle, div.PrefileFronterTitle
	{mso-style-name:PrefileFronterTitle;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:17.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.StylePrefileFronterTitleLeft, li.StylePrefileFronterTitleLeft, div.StylePrefileFronterTitleLeft
	{mso-style-name:"Style PrefileFronterTitle + Left";
	margin-top:0in;
	margin-right:-.2in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:17.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.BillHead
	{mso-style-name:BillHead;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BillHeading2
	{mso-style-name:BillHeading2;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BillLanguage
	{mso-style-name:BillLanguage;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.HangingAnAct, li.HangingAnAct, div.HangingAnAct
	{mso-style-name:HangingAnAct;
	mso-style-link:"HangingAnAct Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.HangingAnActChar
	{mso-style-name:"HangingAnAct Char";
	mso-style-link:HangingAnAct;
	letter-spacing:.2pt;}
span.11ptChar
	{mso-style-name:11ptChar;
	font-family:"Times New Roman",serif;}
span.BillHeadUnBold
	{mso-style-name:BillHeadUnBold;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
p.bpuBill, li.bpuBill, div.bpuBill
	{mso-style-name:bpuBill;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:26.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuHeadSpon, li.bpuHeadSpon, div.bpuHeadSpon
	{mso-style-name:bpuHeadSpon;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.bpuHeadSponChar
	{mso-style-name:bpuHeadSponChar;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuIntro, li.bpuIntro, div.bpuIntro
	{mso-style-name:bpuIntro;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.bpuLegislature, li.bpuLegislature, div.bpuLegislature
	{mso-style-name:bpuLegislature;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:24.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuNormText, li.bpuNormText, div.bpuNormText
	{mso-style-name:bpuNormText;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.bpuReprint, li.bpuReprint, div.bpuReprint
	{mso-style-name:bpuReprint;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:22.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.bpuSponsor, li.bpuSponsor, div.bpuSponsor
	{mso-style-name:bpuSponsor;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuState, li.bpuState, div.bpuState
	{mso-style-name:bpuState;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:32.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.charMarlett
	{mso-style-name:charMarlett;
	font-family:Marlett;}
p.ElevenPt, li.ElevenPt, div.ElevenPt
	{mso-style-name:ElevenPt;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPage12pt, li.FronterPage12pt, div.FronterPage12pt
	{mso-style-name:FronterPage12pt;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPageBillHeading, li.FronterPageBillHeading, div.FronterPageBillHeading
	{mso-style-name:FronterPageBillHeading;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
p.FronterPageNOCAPS, li.FronterPageNOCAPS, div.FronterPageNOCAPS
	{mso-style-name:FronterPageNOCAPS;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times",serif;}
p.FronterPageTBox2, li.FronterPageTBox2, div.FronterPageTBox2
	{mso-style-name:FronterPageTBox2;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPageTextBox, li.FronterPageTextBox, div.FronterPageTextBox
	{mso-style-name:FronterPageTextBox;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.FronterSameAs, li.FronterSameAs, div.FronterSameAs
	{mso-style-name:FronterSameAs;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Pg2Footer, li.Pg2Footer, div.Pg2Footer
	{mso-style-name:Pg2Footer;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Style10pt
	{mso-style-name:"Style 10 pt";
	font-family:"Times New Roman",serif;}
p.StyleFronterPage11pt, li.StyleFronterPage11pt, div.StyleFronterPage11pt
	{mso-style-name:"Style FronterPage + 11 pt";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.StyleFronterPageLoweredby3pt, li.StyleFronterPageLoweredby3pt, div.StyleFronterPageLoweredby3pt
	{mso-style-name:"Style FronterPage + Lowered by  3 pt";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	position:relative;
	top:3.0pt;}
p.StyleFronterSameAsPatternSolid100White, li.StyleFronterSameAsPatternSolid100White, div.StyleFronterSameAsPatternSolid100White
	{mso-style-name:"Style FronterSameAs + Pattern\: Solid \(100%\) \(White\)";
	margin:0in;
	margin-bottom:.0001pt;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Style1, li.Style1, div.Style1
	{mso-style-name:Style1;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.Whereas
	{mso-style-name:Whereas;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
p.bpuWpGraphic, li.bpuWpGraphic, div.bpuWpGraphic
	{mso-style-name:bpuWpGraphic;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.LeftBrackt
	{mso-style-name:LeftBrackt;
	font-family:"Albertus Extra Bold",sans-serif;
	font-weight:bold;}
span.RightBrackt
	{mso-style-name:RightBrackt;
	font-family:"Albertus Extra Bold",sans-serif;
	font-weight:bold;}
span.Superscript
	{mso-style-name:Superscript;
	font-family:"Albertus",sans-serif;
	font-weight:bold;
	vertical-align:super;}
p.sponUdate, li.sponUdate, div.sponUdate
	{mso-style-name:sponUdate;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.BoldItal
	{mso-style-name:BoldItal;
	font-weight:bold;
	font-style:italic;}
p.amendfooter, li.amendfooter, div.amendfooter
	{mso-style-name:amendfooter;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.HangingSup, li.HangingSup, div.HangingSup
	{mso-style-name:HangingSup;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.HangingTableBottom, li.HangingTableBottom, div.HangingTableBottom
	{mso-style-name:HangingTableBottom;
	margin-top:0in;
	margin-right:1.0in;
	margin-bottom:0in;
	margin-left:.8in;
	margin-bottom:.0001pt;
	text-indent:-.8in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.HangingTableTop, li.HangingTableTop, div.HangingTableTop
	{mso-style-name:HangingTableTop;
	margin-top:0in;
	margin-right:.5in;
	margin-bottom:0in;
	margin-left:.8in;
	margin-bottom:.0001pt;
	text-indent:-.8in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Segoe UI",sans-serif;
	letter-spacing:.2pt;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:8.5in 14.0in;
	margin:1.5in 1.0in 1.0in 1.0in;}
div.WordSection1
	{page:WordSection1;}
@page WordSection2
	{size:8.5in 14.0in;
	margin:1.5in 113.75pt 1.0in 113.75pt;}
div.WordSection2
	{page:WordSection2;}
@page WordSection3
	{size:8.5in 14.0in;
	margin:1.0in 1.75in 1.2in 2.0in;}
div.WordSection3
	{page:WordSection3;}
-->
</style>

</head>

<body lang=EN-US>

<div class=WordSection1>

<p class=bpuBill><a name=bpuFrontPg></a>ASSEMBLY, No. 1646 </p>

<p class=bpuWpGraphic></p>

<p class=bpuState>STATE OF NEW JERSEY</p>

<p class=bpuLegislature>221st LEGISLATURE</p>

<p class=bpuWpGraphic>  </p>

<p class=bpuIntro>PRE-FILED FOR INTRODUCTION IN THE 2024 SESSION</p>

<p class=bpuIntro>&nbsp;</p>

</div>

<span style='font-size:12.0pt;line-height:120%;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:auto'>
</span>

<div class=WordSection2>

<p class=bpuIntro>&nbsp;</p>

<p class=bpuSponsor>Sponsored by:</p>

<p class=bpuSponsor>Assemblywoman  HEATHER SIMMONS</p>

<p class=bpuSponsor>District 3 (Cumberland, Gloucester and Salem)</p>

<p class=bpuSponsor>Assemblyman  DAVID BAILEY, JR.</p>

<p class=bpuSponsor>District 3 (Cumberland, Gloucester and Salem)</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>SYNOPSIS</p>

<p class=bpuNormText>     Establishes prescription drug pricing disclosure
requirements and measures to reduce prescription drug costs. </p>

<p class=bpuNormText>&nbsp;</p>

<p class=bpuSponsor>CURRENT VERSION OF TEXT </p>

<p class=bpuNormText>     Introduced Pending Technical Review by Legislative
Counsel.</p>

<p class=bpuNormText>   </p>

</div>

<span style='font-size:10.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div class=WordSection3>

<p class=HangingAnAct style='line-height:150%'><span class=BillHead>An Act</span><span
class=HangingAnActChar> concerning prescription drugs and supplementing various
parts of the statutory law.</span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     <span class=BillHeading2>Be It
Enacted </span><span class=BillLanguage>by the Senate and General Assembly of
the State of New Jersey:</span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     1.    As used in section 1 and
sections 3 through 7 of this act:</p>

<p class=MsoNormal style='line-height:150%'>     Director means the Director
of the Division of Consumer Affairs in the Department of Law and Public Safety.</p>

<p class=MsoNormal style='line-height:150%'>     Division means the Division
of Consumer Affairs in the Department of Law and Public Safety.</p>

<p class=MsoNormal style='line-height:150%'>     Essential off-patent or
generic drug or biological product means any prescription drug or biological
product, including any drug-device or biological product-device combination
product for the delivery of the prescription drug or biological product: </p>

<p class=MsoNormal style='line-height:150%'>     (1)   that is made available
for sale in the State; </p>

<p class=MsoNormal style='line-height:150%'>     (2)   for which all exclusive
marketing rights, if any, granted under the 52 Stat. 1040, 21 U.S.C. s.301 et
seq., section 351 of the &quot;Public Health Service Act,&quot; 58 Stat. 682,
42 U.S.C. s.262, and federal patent law, have expired;</p>

<p class=MsoNormal style='line-height:150%'>     (3)   that is actively
manufactured and marketed by three or fewer manufacturers; and </p>

<p class=MsoNormal style='line-height:150%'>     (4) that appears on the
current Model List of Essential Medicines adopted by the World Health
Organization or has been designated by the Commissioner of Health as an
essential medicine due to its efficacy in treating a life-threatening health
condition or a chronic health condition that substantially impairs a persons
ability to engage in activities of daily living.</p>

<p class=MsoNormal style='line-height:150%'>     FDA means the federal Food
and Drug Administration.</p>

<p class=MsoNormal style='line-height:150%'>     Price gouging means any
unconscionable increase in the price of a prescription drug or biological
product.</p>

<p class=MsoNormal style='line-height:150%'>     Unconscionable increase
means an increase in the price of a prescription drug or biological product
that:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   is excessive and not
justified by the cost of producing the drug or biological product or the cost
of appropriate expansion of access to the drug or biological product to promote
the public health; and</p>

<p class=MsoNormal style='line-height:150%'>     (2)   results in consumers for
whom the drug or biological product has been prescribed having no alternative
but to purchase the drug or biological product at an excessive price because of
the importance of the drug to the health of the consumers and insufficient
competition in the market for the drug or biological product.</p>

<p class=MsoNormal style='line-height:150%'>     Wholesale acquisition cost
means<span style='letter-spacing:0pt'>, with respect to a drug </span>or
biological product<span style='letter-spacing:0pt'>, the manufacturer's list
price for the drug </span>or biological product<span style='letter-spacing:
0pt'> to wholesalers or direct purchasers in the United States, not including
prompt pay or other discounts, rebates, or reductions in price, for the most
recent month for which the information is available, as reported in wholesale
price guides or other publications of drug </span>or biological product<span
style='letter-spacing:0pt'> pricing data.</span></p>

<p class=MsoNormal style='line-height:150%'><span style='letter-spacing:0pt'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:150%'>     2.    a.  A pharmacy benefits
manager shall disclose in the contract between the pharmacy benefits manager
and the purchaser each of the following:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   The basis of the
methodology and sources utilized to establish multiple source generic pricing. 
Applicable lists shall be updated and provided to the purchaser whenever there
is a change;</p>

<p class=MsoNormal style='line-height:150%'>     (2)   If a pharmacy benefits
manager utilizes a multiple source generic list for drugs and biological
products dispensed at retail, but does not utilize a similar list for drugs
dispensed by mail.  This practice shall be disclosed to the purchaser in writing
either in the contract or no later than 21 business days from the
implementation of the practice; and</p>

<p class=MsoNormal style='line-height:150%'>     (3)   Whether or not the
pharmacy benefits manager is using the identical multiple source generic drug
and biological products list with respect to billing the purchaser as it does
when reimbursing all network pharmacies.  If multiple source generic drug and
biological products lists are used, the pharmacy benefits manager shall
disclose any difference between the amount paid to any pharmacy and the amount
charged to the purchaser.</p>

<p class=MsoNormal style='line-height:150%'>     b.    A pharmacy benefits
manager shall provide a toll-free telephone number through which a contracted
pharmacy or a consumer may contact the pharmacy benefits manager and speak with
a New Jersey-licensed pharmacist to resolve issues pertaining to benefits
coverage, drug and biological products pricing and prescription drug and
biological products safety.  Callers shall not be placed on hold for longer
than five minutes.  The pharmacy benefits manager shall resolve concerns within
24 hours after receiving the inquiry.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     3.    a.  There is established
in the Division of Consumer Affairs in the Department of Law and Public Safety
the Prescription Drug and Biological Product Review Commission, which shall
consist of nine members: the Commissioners of Health and Human Services and the
Director of the Division of Consumer Affairs, or their designees, who shall
serve ex officio; two public members appointed by the Governor; one public
member appointed by the President of the Senate; one public member appointed by
the Senate Minority Leader; one public member appointed by the Speaker of the
General Assembly; and one public member appointed by the Assembly Minority
Leader.  The public members shall have a significant health care background.</p>

<p class=MsoNormal style='line-height:150%'>     b.    Each public member shall
serve for a term of five years, except that of the six members first appointed,
the first two appointed shall serve for terms of five years, the second two
appointed shall serve for terms of four years, and the third two appointed
shall serve for terms of three years.  Each member shall hold office for the
term of appointment and until their successor is appointed and qualified.</p>

<p class=MsoNormal style='line-height:150%'>     c.     Any vacancy in the
membership of the commission shall be filled for the unexpired term in the manner
provided for the original appointment.  Members are eligible for reappointment
to the commission.</p>

<p class=MsoNormal style='line-height:150%'>     d.    The commission shall
organize as soon as possible after the appointment of its members and shall
annually elect a chairperson and vice-chairperson from among its members, and a
secretary who need not be a member of the commission.  The commission shall
meet at least four times a year and may hold additional meetings as necessary
to discharge its duties.  In addition to such meetings, the commission shall
meet at the call of the chairperson or the director.</p>

<p class=MsoNormal style='line-height:150%'>     e.     A majority of the
membership of the commission shall constitute a quorum for the transaction of
commission business.</p>

<p class=MsoNormal style='line-height:150%'>     f.     Members of the
commission shall serve without compensation, but shall be compensated and
reimbursed for actual expenses reasonably incurred in the performance of their
official duties, and provided with office and meeting facilities required for
the proper conduct of the commission's business.</p>

<p class=MsoNormal style='line-height:150%'>     g.    The division shall
provide staff support to the commission as shall be necessary for the
commission to carry out its duties.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     4.    a.     The commission
shall develop a list of critical prescription drugs and biological products
made available in New Jersey for which there is a substantial public interest
in understanding the development of pricing for the drugs or biological
products. In developing the list, the commission shall consider the following
factors:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   the cost of the drug or
biological product to public health care programs including, but not limited
to, the Medicaid and NJ FamilyCare programs;</p>

<p class=MsoNormal style='line-height:150%'>     (2)   the current cost of the
drug or biological product in the State;</p>

<p class=MsoNormal style='line-height:150%'>     (3)   the extent of
utilization of the drug or biological product within the State; </p>

<p class=MsoNormal style='line-height:150%'>     (4)   the availability and
cost of comparable or therapeutically equivalent courses of treatment; </p>

<p class=MsoNormal style='line-height:150%'>     (5)   the rate at which the
drug or biological product is deemed to produce successful outcomes when used
to treat the conditions for which it is most commonly prescribed; and</p>

<p class=MsoNormal style='line-height:150%'>     (6)   other objectively
quantifiable factors as the commission determines to be relevant to evaluating
the significance of the availability of the drug or biological product in New
Jersey.</p>

<p class=MsoNormal style='line-height:150%'>     The commission may
additionally consider recommendations for drugs and biological products to be
included in the list as may be submitted by: government agencies; members of
the public; and professional organizations representing the pharmaceutical
industry; health care practitioners; pharmaceutical manufacturers; and managed
care plans, prescription drug benefit managers, and other insurers.  The list
shall be reviewed and updated at least once every three years.</p>

<p class=MsoNormal style='line-height:150%'>     b.    For each prescription
drug and biological product that the commission places on the critical
prescription drug and biological product list pursuant to subsection a. of this
section, the commission shall require the manufacturer of the drug or
biological product to report the following information to the commission:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   total cost of
production, and approximate cost of production per dose;</p>

<p class=MsoNormal style='line-height:150%'>     (2)   research and development
costs of the drug or biological product, including:</p>

<p class=MsoNormal style='line-height:150%'>     (a)   research and development
costs that are paid with public funds;</p>

<p class=MsoNormal style='line-height:150%'>     (b)   after-tax research and
development costs paid by the manufacturer; and</p>

<p class=MsoNormal style='line-height:150%'>     (c)   research and development
costs paid by third parties;</p>

<p class=MsoNormal style='line-height:150%'>     (3)   marketing and
advertising costs for the drug or biological product, apportioned by marketing
activities that are directed to consumers, marketing activities that are
directed to prescribers, and the total cost of all marketing and advertising
that is directed primarily to New Jersey consumers and prescribers;</p>

<p class=MsoNormal style='line-height:150%'>     (4)   the prices for the drug
or biological product that are charged to purchasers outside the United States,
by country, for a representative set of countries determined by the commission;</p>

<p class=MsoNormal style='line-height:150%'>     (5)   prices charged to
typical New Jersey purchasers, including, but not limited to, pharmacies,
pharmacy chains, pharmacy wholesalers, or other direct purchasers; </p>

<p class=MsoNormal style='line-height:150%'>     (6)   true net typical prices
charged to pharmacy benefit managers for distribution in New Jersey, net of any
rebates or other payments from the manufacturer to the pharmacy benefit manager
and the pharmacy benefit manager to the manufacturer; and</p>

<p class=MsoNormal style='line-height:150%'>     (7)   any rebates that are
available to consumers, which information shall be made publically available on
the divisions website.</p>

<p class=MsoNormal style='line-height:150%'>     c.     The commission shall
adopt, pursuant to the Administrative Procedure Act, P.L.1968, c.410
(C.52:14B-1 et seq.), rules and regulations to further define and enforce the
provisions of this section, which may include monetary penalties for failure to
comply with the requirements of this section.</p>

<p class=MsoNormal style='line-height:150%'>     d.    Information reported
pursuant to subsection b. of this section shall not be deemed to be a public or
government record under P.L.1963, c.73 (C.47:1A-1 et seq.) or P.L.2001, c.404
(C.47:1A-5&nbsp;et&nbsp;al.).&nbsp;Any public reporting of information
submitted pursuant to subsection b. of this section shall be aggregated to
protect the financial, competitive, or proprietary nature of the information.</p>

<p class=MsoNormal style='line-height:150%'>     e.     The commission shall
prepare an annual report on prescription drug and biological product prices and
their role in overall health care spending in the State based on the data
submitted to the commission pursuant to subsection b. of this section and in conformance
with the provisions of subsection d. of this section.  As part of the report,
the commission may include recommendations for actions to lower prescription
drug and biological product costs and spending across the State while
maintaining access to, and the quality of, health care. The commission shall
submit the report to the Governor, and, pursuant to section 2 of P.L.1991,
c.164 (C.52:14-19.1), to the Legislature, and shall make the report available
on the divisions website.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     5.    a. The commission shall
identify, using information submitted to the commission pursuant to section 3
of this act, those prescription drugs and biological products that have a cost
in New Jersey that is excessively high when compared with the cost of the drug
in other states and countries and when compared with the overall cost of
researching, developing, and producing the drug or biological product in light
of the number of years the drug or biological product has been made available
for distribution.</p>

<p class=MsoNormal style='line-height:150%'>     b.    If the commission
determines that the cost of a prescription drug or biological product is
excessively high, the commission may set the maximum allowable price that the
manufacturer can charge for that prescription drug or biological product when
sold for use in New Jersey.  The maximum price set by the commission shall be
commensurate with the price of the drug in other states and countries, with
full consideration of the overall cost of researching, developing, and
producing the drug or biological product in light of the number of years the
drug or biological product has been made available for distribution.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     6.    a.  A prescription drug
or biological product manufacturer or wholesale distributor shall not engage in
price gouging in the sale of an essential off-patent or generic drug or
biological product.  </p>

<p class=MsoNormal style='line-height:150%'>     b.    It shall not constitute
a violation of subsection a. of this section for a wholesale distributor to
increase the price of an essential off-patent or generic drug or biological
product if the price increase is directly attributable to additional costs for
the drug or biological product imposed on the wholesale distributor by the
manufacturer of the drug or biological product.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     7.    a.  The director may
notify the Attorney General of any increase in the price of an essential
off-patent or generic drug or biological product whenever: </p>

<p class=MsoNormal style='line-height:150%'>     (1)   the price increase,
individually or in combination with other price increases:</p>

<p class=MsoNormal style='line-height:150%'>     (a)   would result in an
increase of 50 percent or more in the wholesale acquisition cost of the drug or
biological product within the preceding one-year period; or</p>

<p class=MsoNormal style='line-height:150%'>     (b)   would result in an
increase of 50 percent or more in the price paid by the Medicaid program or NJ
FamilyCare program for the drug or biological product within the preceding
one-year period, as certified by the Director of the Division of Medical
Assistance and Health Services in the Department of Human Services; and</p>

<p class=MsoNormal style='line-height:150%'>     (2)   (a)  a 30-day supply of
the maximum recommended dosage of the drug or biological product for any
indication, according to the FDA-approved label for the drug or biological
product, would cost more than $80 at the wholesale acquisition cost of the drug
or biological product;</p>

<p class=MsoNormal style='line-height:150%'>     (b)   a full course of
treatment with the drug or biological product, according to the FDA-approved
label for the drug or biological product, would cost more than $80 at the
wholesale acquisition cost of the drug or biological product; or</p>

<p class=MsoNormal style='line-height:150%'>     (c)   if the drug or
biological product is made available to consumers only in quantities that do
not correspond to a 30-day supply, a full course of treatment, or a single
dose, the drug or biological product would cost more than $80 at the wholesale
acquisition cost of the drug or biological product to obtain a 30-day supply or
a full course of treatment.</p>

<p class=MsoNormal style='line-height:150%'>     b.    At the request of the
Attorney General, the manufacturer of an essential off-patent or generic drug
or biological product identified in a notice provided pursuant to subsection a.
of this section shall, no later than 45 days after receipt of the request,
submit a statement to the Attorney General:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   itemizing the components
of the cost of producing the drug or biological product;</p>

<p class=MsoNormal style='line-height:150%'>     (2) identifying the
circumstances and timing of any increase in materials or manufacturing costs
that caused any increase in the price of the drug or biological product within
the one-year period preceding the date of the price increase;</p>

<p class=MsoNormal style='line-height:150%'>     (3)   identifying the
circumstances and timing of any expenditures made by the manufacturer to expand
access to the drug or biological product and explaining any improvement in
public health associated with those expenditures; and</p>

<p class=MsoNormal style='line-height:150%'>     (4)   providing any other
information that the manufacturer believes to be relevant to a determination as
to whether a violation of P.L.    , c.    (C.        ) (pending before the
Legislature as this bill) has occurred.</p>

<p class=MsoNormal style='line-height:150%'>     c.     The Attorney General
may require a manufacturer or a wholesale distributor to produce any records or
documents that may be relevant to a determination as to whether a violation of
this act has occurred.</p>

<p class=MsoNormal style='line-height:150%'>     d.    Upon petition of the
Attorney General, a court may issue an order:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   compelling a
manufacturer to submit the statement required pursuant to subsection b. of this
section or a manufacturer or wholesale distributor to produce specific records
or documents as requested by the Attorney General pursuant to subsection c. of
this section;</p>

<p class=MsoNormal style='line-height:150%'>     (2)   restraining or enjoining
a violation of this act;</p>

<p class=MsoNormal style='line-height:150%'>     (3)   restoring to any
consumer, including any third party payor, any money acquired by a manufacturer
or wholesale distributor as a result of a price increase that violates this
act;</p>

<p class=MsoNormal style='line-height:150%'>     (4)   requiring a manufacturer
that has engaged in price gouging in the sale of an essential off-patent or
generic drug or biological product to make the drug or biological product
available to wholesale distributors, pharmacies, and consumers in the State,
for a period of up to one year, at a price that does not exceed the price at
which the drug or biological product was made available to such wholesale
distributors, pharmacies, and consumers immediately prior to the violation of
this act; and</p>

<p class=MsoNormal style='line-height:150%'>     (5)   assessing a civil
penalty of up to $10,000 against a manufacturer or wholesale distributor for
each violation of this act.  For the purposes of this paragraph, each sale of
an essential off-patent or generic drug or biological product at a price that
constitutes price gouging shall be deemed to be a separate violation.</p>

<p class=MsoNormal style='line-height:150%'>     e.     The Attorney General
shall not commence an action seeking relief pursuant to paragraphs (2) through
(5) of subsection d. of this section unless the Attorney General has provided
the manufacturer or wholesale distributor an opportunity to meet with the
Attorney General to provide a justification for the increase in the price of
the essential off-patent or generic drug or biological product.</p>

<p class=MsoNormal style='line-height:150%'>     f.     Any information
provided by a manufacturer pursuant to subsection b. of this section, or by a
manufacturer or wholesale distributor pursuant to subsection c. of this
section, shall be deemed confidential and shall not be disclosed to the public
or otherwise subject to public access, inspection, or copying, unless such
confidentiality is waived by the manufacturer or wholesale distributor.</p>

<p class=MsoNormal style='line-height:150%'>     g.    It shall not be a
defense to an action brought by the Attorney General pursuant to subsection d.
of this section that a manufacturer alleged to have violated this act did not
sell the essential off-patent or generic drug or biological product directly to
a consumer in this State.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     8.    The Director of the
Division of Consumer Affairs in the Department of Law and Public Safety shall,
pursuant to the Administrative Procedure Act, P.L.1968, c.410
(C.52:14B-1&nbsp;et&nbsp;seq.),&nbsp;adopt rules and regulations as shall be
necessary to implement the provisions of this act. <br clear=all
style='page-break-before:always'>
</p>

<p class=MsoNormal style='line-height:150%'>     9.    This act shall take
effect on the 180th day after the date of enactment and shall apply to all
contracts or agreements for pharmacy benefits management services that are
executed or renewed on or after the effective date.  The Director of the
Division of Consumer Affairs in the Department of Law and Public Safety may
take any administrative action in advance as may be necessary to implement the
provisions of this act.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:150%'>STATEMENT</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     This bill provides for
prescription drug disclosure requirements and measures to reduce costs for
prescription drugs and biological products costs.</p>

<p class=MsoNormal style='line-height:150%'>     Under the bill, pharmacy
benefits managers (PBMs) are required to disclose certain information about
prescription drug and biological product pricing and generic substitutions to
benefit plan purchasers.  The bill requires PBMs to establish a toll-free telephone
number through which consumers and pharmacists can quickly obtain information
regarding coverage, pricing and prescription drug and biological product
safety. </p>

<p class=MsoNormal style='line-height:150%'>     With respect to purchasers of
pharmacy benefits management services, this bill requires PBMs to disclose, in
the contract entered into between the purchaser and the PBM, the methodology
and sources utilized to determine multiple source generic drug  and biological
product pricing. That pricing information shall be updated whenever a change occurs
and must be provided to the purchaser.  If a PBM uses a multiple source generic
list for drugs and biological product dispensed at retail, but not for drugs
and biological products dispensed by mail, this must be disclosed in the
contract as well, or within 21 business days from the implementation of the
practice.  In addition, the bill requires PBMs to disclose to purchasers
whether the multiple source generic pricing list used to bill the purchaser is
the same as the list used to reimburse pharmacies.  If the lists are not the
same, the difference between the amount paid to the pharmacy and the amount
charged to the purchaser shall be disclosed.</p>

<p class=MsoNormal style='line-height:150%'>     This bill also requires PBMs
to provide a toll-free telephone number for consumers and contracted pharmacies
to speak with a New Jersey-licensed pharmacist concerning benefits coverage,
drug and biological product pricing and prescription drug safety.  Callers may
not be placed on hold for longer than five minutes, and concerns must be
resolved within 24 hours.</p>

<p class=MsoNormal style='line-height:150%'>     This bill establishes the
Prescription Drug and Biological Product Review Commission in the Division of
Consumer Affairs in the Department of Law and Public Safety, which will be
tasked with developing a list of critical prescription drugs and biological
products for which drug and biological product manufacturers will be required
to report certain information concerning development, production, and marketing
costs.  If the commission determines that a drug or biological product is
priced excessively high in New Jersey, it will have the authority to establish
a maximum price for the drug or biological product in the State.  The
commission will consist of nine members.</p>

<p class=MsoNormal style='line-height:150%'>     In developing the list of
critical prescription drugs and biological products, the commission will
consider: the cost of the drug or biological product in the State, including
the cost to public health care programs; the extent of utilization of the drug
or biological product within the State; the availability and cost of comparable
or therapeutically equivalent courses of treatment; the rate of successful
treatment outcomes for the drug or biological product; other objectively
quantifiable factors as the commission determines to be relevant. The
commission may additionally consider recommendations for drugs and biological
products to be included in the list made by government agencies, members of the
public, and professional organizations.  The commission will be required to
review and update the list at least once every three years.</p>

<p class=MsoNormal style='line-height:150%'>     For each prescription drug and
biological product that the commission places on the critical prescription drug
list, the manufacturer of the drug or biological product will be required to
report information concerning: the total cost of production and approximate
cost of production per dose; research and development costs; marketing and
advertising costs; the prices for the drug or biological product that are
charged to purchasers outside the United States for a representative set of
countries determined by the commission; prices charged to typical New Jersey
purchasers; true net typical prices charged to pharmacy benefit managers; and
any rebates that are available to consumers which information is to be made
publically available.</p>

<p class=MsoNormal style='line-height:150%'>     Using information submitted
under the bill, the commission will identify prescription drugs and biological
products that have a cost in New Jersey that is excessively high when compared
with the cost of the drug or biological product in other states and countries
and when compared with the overall cost of researching, developing, and
producing the drug or biological product in light of the number of years the
drug or biological product has been made available for distribution.  For
prescription drugs and biological products with an excessively high cost, the
commission will be permitted to set the maximum allowable price that the
manufacturer can charge for that prescription drug or biological product in New
Jersey, which is to be commensurate with the price of the drug in other states
and countries, with full consideration of the overall cost of researching,
developing, and producing the drug or biological product in light of the number
of years the drug or biological product has been made available for
distribution.  </p>

<p class=MsoNormal style='line-height:150%'>     This bill also prohibits
manufacturers and wholesale distributors of prescription drugs and biological
products from excessively increasing the price of certain prescription drugs
and biological products without justification.</p>

<p class=MsoNormal style='line-height:150%'>     Specifically, manufacturers
and wholesale distributors may not engage in price gouging in the sale of an
essential off-patent or generic drug or biological product.  Price gouging is
defined to mean an increase in the price of a drug or biological product that:
(1) is excessive and not justified by the cost of producing the drug or
biological product or expanding access to the drug or biological product to
promote the public health; and (2) results in consumers having no alternative
but to purchase the drug or biological product at an excessive price because of
the importance of the drug or biological product to their health and
insufficient marketplace competition.  Under the bill, wholesale distributors
will not be found to have violated this prohibition if the distributor
increases the price of a drug or biological product in direct response to
additional costs for the drug or biological product imposed on the distributor
by the manufacturer.</p>

<p class=MsoNormal style='line-height:150%'>     The bill defines essential
off-patent or generic drug or biological product to mean any prescription drug
or biological product, including any drug-device or biological product-device
combination product for the delivery of the prescription drug or biological
product: (1) that is made available for sale in the State; (2) for which all
exclusive marketing rights granted under federal law have expired; (3) that is
actively manufactured and marketed by three or fewer manufacturers; and (4)
that appears on the current Model List of Essential Medicines adopted by the
World Health Organization or has been otherwise designated as an essential
medicine by the Commissioner of Health.</p>

<p class=MsoNormal style='line-height:150%'>     The Director of the Division
of Consumer Affairs in the Department of Law and Public Safety may notify the
Attorney General of any increase in the price of an essential off-patent or
generic drug or biological product whenever: (1) the price increase,
individually or in combination with other price increases, would result in an
increase of 50 percent or more in the wholesale acquisition cost for the drug
or biological product or in the price paid for the drug or biological product
by the State Medicaid or NJ FamilyCare programs within a one-year period; and
(2) the wholesale acquisition cost of the drug or biological product is more
than $80 for a 30-day supply or a full course of treatment.</p>

<p class=MsoNormal style='line-height:150%'>     At the request of the Attorney
General, the manufacturer of an essential off-patent or generic drug or
biological product identified in a notice provided under the bill will be
required to submit, within 45 days of receiving the request, a statement to the
Attorney General: (1) detailing the cost of producing the drug or biological
product; (2) identifying the circumstances and timing of any cost increases in
the preceding year; (3) identifying the circumstances and timing of any
expenditures made by the manufacturer to expand access to the drug or
biological product, and explaining any resulting improvements in public health;
and (4) any other information the manufacturer determines to be relevant to a
determination as to whether a violation of the provisions of the bill has
occurred.</p>

<p class=MsoNormal style='line-height:150%'>     The Attorney General may
require a manufacturer or a wholesale distributor to produce any records or
documents that may be relevant to a determination as to whether a violation of
the bill has occurred.  The Attorney General may additionally petition for a
court order: compelling submission of any required statement or records;
restraining or enjoining a violation of the bill; restoring to any consumer,
including any third party payor, any money acquired by the manufacturer or
wholesale distributor as a result of a price increase that violates the bill;
requiring a manufacturer that has engaged in price gouging to make the drug or
biological product available in the State, for a period of up to one year, at a
price that does not exceed the price immediately prior to the violation; and
assessing a civil penalty of up to $10,000 against a manufacturer or wholesale
distributor who has violated the provisions of the bill.  For the purposes of
assessing the civil penalty, each sale of a drug or biological product at a
price that constitutes price gouging will be deemed a separate violation.  </p>

<p class=MsoNormal style='line-height:150%'>     Any information provided by a
manufacturer or wholesale distributor under the bill will be confidential and may
not be disclosed to the public or otherwise subjected to public access,
inspection, or copying, unless the manufacturer or wholesale distributor waives
confidentiality.</p>

</div>

</body>

</html>
